The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives described below.
Applications in response to this NOSI must be submitted using the following targeted funding opportunity:
- PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
- The funding instrument, or activity code, will be the same as the parent award. All activity codes of currently funded NIAID grants are eligible.
- Please note: NOT-AI-20-034 is specific for PA-20-135. NIH grantees seeking additional funds for research responsive to the SARS-CoV-2/COVID-19 outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).
Applications will be accepted on a rolling basis 03/25/2020 from 03/25/2021 through 5:00 PM local time of the applicant organization. An application submitted in response to this NOSI that is received on 03/25/2021 or later, will be withdrawn.
Areas of Interest
In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:
- Studies to identify optimal in vitroculture requirements and conditions;
- Development of reagents and assays for virus characterization;
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- Studies to identify viral epitopes critical for binding neutralization;
- Studies to examine virus stability and persistence;
- Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
- Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
- Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
- Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
- Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
- Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;
- Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
- Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.